Exelixis Inc
EXELNASDAQHealthcare · Biological Products, (no Diagnostic Substances)
Market cap
$12.60B
Employees
1,077
Exchange
NASDAQ
Headquarters
ALAMEDA, CA
About Exelixis Inc
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Industry
Biological Products, (no Diagnostic Substances)
Sector
Healthcare
Country
US
Website
www.exelixis.com